By
admin
#article_normal, #Biological Therapy, #Biopharmaceuticals, #Biotechnology, #Breakthrough, #Cancer, #Cancer Drugs, #CELC, #Celcuity, #designation, #drug, #general news, #Health, #Healthcare, #Healthcare Provision, #Healthcare/Life Sciences, #Hours, #life sciences, #Medical Conditions, #medications, #Pharmaceuticals, #Political, #Political/General News, #soars, #specialized drugs, #Specialized Drugs/Medications, #Stock, #Therapy, #US15102K1007
Shares of Celcuity Inc. CELC were up 17% at $10.80 after hours as the U.S. Food and Drug Administration granted Breakthrough Therapy designation for a cancer drug.
The designation is for gedatolisib for certain patients with HR+/HER2- metastatic breast cancer.
Gedatolisib received Fast Track designation from the FDA in January.
Celcuity…
